PC 4 - Management of localised prostate cancer

1. To explain what kind of information the radiologist needs to provide to the MDT.
2. To illustrate the impact of this information on the correct diagnosis, staging and treatment stratification.
3. To stress the importance of MDT meetings in radiological quality assurance.

1. To understand how clinical, biological, radiological and pathological information influence clinical decision-making and informed consent.
2. To explore current treatment options and modern algorithms in patients with low to high-risk prostate cancer.

1. To be able to correctly understand the information given by the pathologist, in order to decide the best treatment according to the pathology report.
2. To understand the complexity of the molecular underpinnings in the setting of prostate cancer, and to understand the correlation between molecular changes and prostate cancer histology.

1. To understand that early detection through risk-based population screening will save lives and prevent unnecessary treatments.
2. To explain that in low-risk prostate cancer, "active surveillance and watchful waiting" is the only option according to the EAU guidelines, but that this treatment needs a good explanation to the patient.
3. To learn that from a patient's perspective, learning of side effects is equally important as learning what the clinician can do when they happen to help the patient.